Advertisement
Table 6 Blood–CSF barrier function and albumin levels
| Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | |
|---|---|---|---|---|---|---|
| QAlb > Qlim(Alb) | Patients | 4/10 (40) | 15/22 (68.2) | 9/15 (60) | 6/7 (85.7) | n.d. |
| QAlb > Qlim(Alb) | Samples | 4/17 (23.5) | 30/43 (69.8) | 16/26 (61.5) | 14/17 (82.4) | 75/147 (51%) |
| QAlb, all LPs | – | 4.81 (3.01–10.8; 17) | 8.39 (2.1–33.9; 42) | 7.3 (2.1–33.9; 25) | 9 (3.3–20.7; 17) | 7 (2.3–57.1; 137) |
| QAlb, QAlb pos. | – | 8.53 (6.3–10.8; 4) | 9.8 (6.4–33.9; 29) | 9 (6.4–33.9; 15) | 10.25 (6.8––20.7; 14) | 11.8 (5.63–57.14; 70) |
| Albumin CSF, all LPs | mg/L | 204 (95–517; 17) | 331 (81.2–726; 41) | 255.5 (81.2–599; 24) | 368 (137–726; 17) | 284 (83.6–1890; 139) |
| Albumin CSF, QAlb pos. | mg/L | 366 (251–517; 4) | 371.5 (227–726; 28) | 312 (227–599; 14) | 431 (282–726; 14) | 437 (219–1890) |
| Albumin serum, all LPs | g/L | 40.6 (29.3–49.5; 17) | 40 (22.6–51.8; 41) | 39.85 (22.6–51.4; 24) | 41.2 (32.7–51.8; 17) | 40.7 (19.7–67.9; 133) |
| Albumin serum, QAlb pos. | g/L | 43.15 (37.7–47.9; 4) | 39.5 (22.6–50.9; 27) | 35.55 (22.6–46.8; 14) | 39.9 (32.7–50.9; 13) | 39 (19.7–55.9) |
| Combined intrathecal IgG synthesis and disturbed blood–CSF barrier function | ||||||
| Patients, at least once | N (%) | 3/10 (30) | 4/20 (20) | 3/13 (23.1) | 1/7 (14.3) | n.d. |
| All LPs | N (%) | 3/17 (17.6) | 5/43 (11.6) | 4/26 (15.4) | 1/17 (5.9) | 13/74 (17.6%) |
